6818 related articles for article (PubMed ID: 2962476)
1. Prognostic and pathogenetic implications of immune complexes in human cancer.
Salinas FA; Wee KH
Adv Immun Cancer Ther; 1986; 2():189-209. PubMed ID: 2962476
[TBL] [Abstract][Full Text] [Related]
2. Significance of breast carcinoma-associated antigens as a monitor of tumor burden: characterization by monoclonal antibodies.
Salinas FA; Wee KH; Ceriani RL
Cancer Res; 1987 Feb; 47(3):907-13. PubMed ID: 3802085
[TBL] [Abstract][Full Text] [Related]
3. Circulating immune complexes in malignant melanoma: serial studies in 130 patients.
Bharwani N; Campbell L; Ashley P; Queen WD; Phillips TM; Jerry LM
Oncology; 1986; 43(3):143-8. PubMed ID: 3703459
[TBL] [Abstract][Full Text] [Related]
4. Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma.
Wong JH; Gupta RK; Morton DL
Arch Surg; 1986 Nov; 121(11):1342-5. PubMed ID: 3778209
[TBL] [Abstract][Full Text] [Related]
5. Immune complexes and human neoplasia.
Salinas FA; Wee KH; Silver HK
Biomed Pharmacother; 1983; 37(5):211-8. PubMed ID: 6362736
[TBL] [Abstract][Full Text] [Related]
6. Biochemical classification of circulating immune complexes in human malignant melanoma and hematologic neoplasms.
Queen WD; Bharwani N; Phillips EA; Ruether BA; Phillips TM; Jerry LM
Oncology; 1989; 46(1):14-25. PubMed ID: 2915889
[TBL] [Abstract][Full Text] [Related]
7. Circulating immune complexes in human malignant melanoma.
D'Amelio R; Cooke B; Hobbs JR
Tumori; 1982 Dec; 68(6):469-72. PubMed ID: 7168010
[TBL] [Abstract][Full Text] [Related]
8. Measurement of a monoclonal antibody-defined, melanoma-associated antigen in human sera: correlation of circulating antigen levels with tumor burden.
Morgan AC; Crane MM; Rossen RD
J Natl Cancer Inst; 1984 Feb; 72(2):243-9. PubMed ID: 6582312
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating immune complexes and urinary antigens in human malignancy.
Huth JF; Gupta RK; Morton DL
Cancer; 1982 Mar; 49(6):1150-7. PubMed ID: 7037157
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance and nature of circulating immune complexes in melanoma patients.
Gupta RK; Morton DL
Contemp Top Immunobiol; 1985; 15():1-53. PubMed ID: 3896641
[No Abstract] [Full Text] [Related]
12. [Circulating immune complexes in the serum of tumor patients].
Alvarez R; García Gómez A; Subiza JL; Domínguez J; Bootello A; Coll J
Rev Esp Oncol; 1982; 29(4):727-34. PubMed ID: 6927370
[TBL] [Abstract][Full Text] [Related]
13. Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Wong JH; Aguero B; Gupta RK; Morton DL
Cancer Immunol Immunother; 1988; 27(2):142-6. PubMed ID: 3046746
[TBL] [Abstract][Full Text] [Related]
14. Hydatid disease: analysis of parasite antigens in circulating immune complexes and in preformed hydatid antigen-antibody complexes.
D'Amelio R; De Rosa F; Pontesilli O; Dayal R; Brighouse G; Teggi A; Barnet M; Lambert PH
Med Microbiol Immunol; 1989; 178(3):177-86. PubMed ID: 2664438
[TBL] [Abstract][Full Text] [Related]
15. Serial circulating immune complex values and development of metastatic disease in breast cancer and malignant melanoma patients.
Ronai Z; Shaham J; Stein J; Sulitzeanu D
Cancer Immunol Immunother; 1986; 22(1):72-5. PubMed ID: 3518930
[TBL] [Abstract][Full Text] [Related]
16. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.
Mittelman A; Chen ZJ; Yang H; Wong GY; Ferrone S
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):466-70. PubMed ID: 1731316
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.
Bukh A; Møller-Larsen A; Aguado MT; Møller-Larsen F; Møller NP
Cancer Immunol Immunother; 1988; 26(3):280-4. PubMed ID: 3260134
[TBL] [Abstract][Full Text] [Related]
19. Circulating immune complexes of Hodgkin's disease contain an antigen that is present in Hodgkin and Reed-Sternberg cells.
Bepler G; Zhen QY; Havemann K
J Cancer Res Clin Oncol; 1985; 110(1):56-64. PubMed ID: 2410427
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma.
Wong JH; Xu SH; Gupta RK; Morton DL
Arch Surg; 1990 Feb; 125(2):187-91. PubMed ID: 2302059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
